Intellia Therapeutics Appoints Edward Dulac as CFO

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has announced the appointment of Edward Dulac as the Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Dulac brings with him more than 20 years of combined finance, business development, and corporate strategy experience, having most recently served as CFO of Fate Therapeutics. He will succeed Glenn Goddard, who is stepping down from his role effective June 30, 2024.

Edward Dulac's extensive background includes multiple positions at Celgene (now Bristol Myers Squibb) and experience as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers, as well as in corporate finance at Pfizer. His educational credentials include a Bachelor of Pharmacy from the University of Pittsburgh and an MBA from Indiana University, Kelley School of Business.

Intellia's President and Chief Executive Officer, John Leonard, M.D., expressed his enthusiasm for Dulac's appointment, emphasizing the critical role his financial and business development experience will play as Intellia expands its leadership position and prepares for future commercial success. Dr. Leonard also took the opportunity to thank Glenn Goddard for his dedicated support and numerous contributions to Intellia's success throughout the company's remarkable growth.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's "in vivo" programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body, while its "ex vivo" programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies.

Today the company's shares have moved -5.7% to a price of $22.64. For the full picture, make sure to review Intellia Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.